Amgen's great osteoporosis hope--denosumab, or D-mab--increased bone strength in women receiving hormone replacement therapy for breast cancer. The first complete analysis of late-stage trial data on the drug showed a 5.5 percent increase in bone density among the women. On Friday, researchers for Amgen noted that the drug increased density in the spongy part of the bone. Amgen has great expectations for denosumab, which has the potential to reach blockbuster status with $1 billion to $2 billion in sales.
"In this study, denosumab data looks promising and, as a clinician, I look forward to having a potential alternative to existing therapies," said lead investigator Dr. Georgiana Kehr Ellis, from the oncology division at the University of Washington School of Medicine in Seattle.
ALSO: Oxford Genome Sciences has inked a deal with Amgen to collaborate on new antibodies for treating cancer. Release
Denosumab: Amgen's salvation? Report
Amgen touts progress in two key programs. Report
Amgen discusses the future with analysts. Report
Analyst: Anemia drug warnings 'not bad'. Report